System1 Announces a $25 Million Series A Funding to Advance Integrated Technology Platform for Neurotherapeutics Discovery SAN FRANCISCO, September 12, 2018-- System1 Biosciences, Inc, a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for neurological and psychiatric disorders, today announced the completion of $25 million in Series A financing. The round was co-led by CRV and Pfizer Ventures with participation from Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb Investment Network, Liquid 2 Ventures, and Boom Capital.